Form 4: Cue Biopharma Director Frederick Driscoll Awarded Stock Options

Director Frederick Driscoll of Cue Biopharma, Inc. received a stock option award for 24,400 shares on January 2, 2025.

Summary

• Frederick Driscoll, a director of Cue Biopharma, Inc., was granted a stock option to purchase 24,400 shares of common stock.
• The options have an exercise price of $1.09 per share.
• The grant date was January 2, 2025.
• The options vest in two tranches: 50% on the six-month anniversary of the grant date and the remaining 50% on the first anniversary.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company for at least one year.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The grant incentivizes the director to contribute to the company's success, which could benefit all stakeholders.

Key Dates